OpenAI, US FDA Discuss AI Integration in Drug Evaluation

tech360.tv
May 8, 2025
1 min read

OpenAI has held multiple meetings with the U.S. Food and Drug Administration to explore the use of artificial intelligence in drug evaluation, according to a report by Wired.

A robotic hand holds glowing tech symbols with hovering icons and "OpenAI" text. Set against a dark background with pink-purple accents.

The discussions reportedly involved a small team from OpenAI and two associates from Elon Musk’s Department of Government Efficiency.

The meetings have taken place over recent weeks, sources familiar with the matter told Wired.

The talks signal growing interest in applying AI to streamline regulatory processes in the healthcare sector.

OpenAI met with the U.S. FDA to discuss AI use in drug evaluation
Meetings included associates from Elon Musk’s Department of Government Efficiency
Discussions occurred multiple times in recent weeks

Source: REUTERS

Global Firms Shift to Cheaper Chinese AI Models Over US Rivals

OnePlus Exits US, Europe Amid Global Smartphone Slump

Twenty-Nine Nations Form World AI Cooperation Organization in Shanghai

Technology increasingly permeates every facet of our lives, making informed decision making an essential pursuit. We bridge this gap by combining the precision of AI with the irreplaceable discernment of human expertise. Our team produces rigorous product reviews that offer unique insights, honest critiques, and trustworthy recommendations. We also leverage AI to synthesise complex news from reliable sources into clear, actionable updates, ensuring that every story is carefully fact checked by our editorial staff before publication. Accuracy remains our priority. Should you identify any discrepancies, please contact us at editorial@tech360.tv. Your feedback is a vital part of our process in maintaining the high standards our readers deserve.